From Financial Modeling Prep: 2025-04-22 13:01:00

Danaher (NYSE:DHR) started 2025 strong, exceeding expectations with adjusted earnings per share of $1.88, revenue of $5.74 billion, and operating profit of $1.27 billion. Shares rose 6% on the news.

The company’s bioprocessing segment and molecular diagnostics, especially in respiratory testing, drove the impressive performance, offsetting macro uncertainties and showcasing Danaher’s portfolio resilience.

Danaher projects low single-digit core revenue growth for Q2 and maintains full-year guidance of earnings per share between $7.60 and $7.75, with expected core revenue growth of around 3% for the year.



Read more at Financial Modeling Prep:: Danaher Jumps 6% as Bioprocessing and Diagnostics …